- ISIN
- US09062X1037
- CUSIP
- 09062X103
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- IPO Date
- Sep 16, 1991
Highlights
- Market Cap
- $29.99B
- Enterprise Value
- $37.86B
- EPS (TTM)
- $5.65
- PE Ratio
- 35.90
- PEG Ratio
- 2.49
- Total Revenue (TTM)
- $9.95B
- Gross Profit (TTM)
- $6.74B
- EBITDA (TTM)
- $1.67B
- Year Range
- $127.00 - $219.72
- Target Price
- $225.00
- ROA (TTM)
- 2.60%
- ROE (TTM)
- 4.43%
- Avg. Volume (1M)
- 1M
- Avg. Volume Value (1M)
- $295.08M
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
BIIB Performance Chart
Biogen Inc. (BIIB) is up 15.3% since the beginning of the year. At $203 per share, BIIB is trading 7.6% below its 52-week high of $220. Investors who bought $1,000 worth of BIIB shares 5 years ago would now be looking at an investment worth $621.
Loading charts...
Compare this symbol against anything
Returns By Period
Biogen Inc. (BIIB) has returned 15.32% so far this year and 53.81% over the past 12 months. Over the last ten years, BIIB has returned -4.75% per year, falling short of the S&P 500 Index benchmark, which averaged 13.26% annually.
Biogen Inc.
- 1D
- -2.40%
- 1M
- -6.09%
- 6M
- 12.82%
- YTD
- 15.32%
- 1Y
- 53.81%
- 3Y*
- -9.00%
- 5Y*
- -9.08%
- 10Y*
- -4.75%
- ALL TIME*
- 12.85%
Benchmark (S&P 500 Index)
- 1D
- 0.70%
- 1M
- 0.09%
- 6M
- 7.94%
- YTD
- 9.41%
- 1Y
- 20.07%
- 3Y*
- 17.84%
- 5Y*
- 11.25%
- 10Y*
- 13.26%
- ALL TIME*
- 8.09%
BIIB Monthly Returns History
Based on dividend-adjusted daily data since Sep 17, 1991, BIIB's average daily return is +0.11%, while the average monthly return is +2.02%. At this rate, an investment would double in approximately 2.9 years.
Historically, 53% of months were positive and 47% were negative. The best month was Jun 2000 with a return of +83.8%, while the worst month was Feb 2005 at -40.5%. The longest winning streak lasted 10 consecutive months, and the longest losing streak was 10 months.
On a daily basis, BIIB closed higher 48% of trading days. The best single day was Nov 4, 2020 with a return of +44.0%, while the worst single day was Feb 28, 2005 at -42.6%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 2.22% | 6.63% | -4.43% | 3.25% | 3.55% | 10.23% | -6.07% | 15.32% | |||||
| 2025 | -5.88% | -2.38% | -2.60% | -11.52% | 7.19% | -3.24% | 1.92% | 3.30% | 5.94% | 10.13% | 18.03% | -3.35% | 15.09% |
| 2024 | -4.68% | -12.03% | -0.63% | -0.38% | 4.71% | 3.06% | -8.03% | -3.96% | -5.33% | -10.24% | -7.68% | -4.80% | -40.91% |
| 2023 | 5.05% | -7.23% | 3.03% | 9.42% | -2.57% | -3.90% | -5.15% | -1.05% | -3.87% | -7.58% | -1.46% | 10.55% | -6.55% |
| 2022 | -5.80% | -6.63% | -0.19% | -1.50% | -3.59% | 1.97% | 5.45% | -9.15% | 36.66% | 6.16% | 7.67% | -9.26% | 15.42% |
| 2021 | 15.42% | -3.44% | 2.52% | -4.44% | 0.06% | 29.46% | -5.64% | 3.73% | -16.50% | -5.76% | -11.60% | 1.77% | -2.02% |
Benchmark Metrics
Biogen Inc. has an annualized alpha of 18.70%, beta of 1.03, and R2 of 0.11 versus S&P 500 Index. Calculated based on daily prices since September 17, 1991.
- This stock captured 126.09% of S&P 500 Index gains and 107.38% of its losses - amplifying both gains and losses, but participating more in upside than downside.
- R2 of 0.11 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 18.70%
- Beta
- 1.03
- R²
- 0.11
- Upside Capture
- 126.09%
- Downside Capture
- 107.38%
Return for Risk
Risk / Return Rank
BIIB ranks 87 for risk / return — above 87% of stocks peers on PortfoliosLab. Its historical combined result is among the stronger results in the peer group.
Risk / Return Metrics
The table below present risk-adjusted performance metrics for Biogen Inc. (BIIB) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| BIIB | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +0.23 | ||
| Sortino ratioReturn per unit of downside risk | +0.42 | ||
| Omega ratioGain probability vs. loss probability | 1.28 | 1.25 | +0.03 |
| Calmar ratioReturn relative to maximum drawdown | 4.10 | 2.00 | +2.10 |
| Martin ratioReturn relative to average drawdown | 9.99 | 8.49 | +1.50 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Biogen Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Biogen Inc. was 89.98%, occurring on Dec 16, 1994. Recovery took 258 trading sessions.
The current Biogen Inc. drawdown is 57.36%.
Drawdown | Fall | Recovery | Underwater | Related event |
|---|---|---|---|---|
-89.98%Dec 1994 | 3y 2mo | 1y 10d | 4y 2moOct 1991 - Dec 1995 | — |
-76.18%Apr 2025 | 10y 21d | — | 11y 4moMar 2015 - now | 2025 selloff2025 |
-66.51%Apr 2000 | 1mo 18d | 5mo 6d | 6mo 24dMar 2000 - Sep 2000 | Dot-com crash2000–2002 |
-62.59%Mar 2003 | 2y 2mo | 4y 7mo | 6y 10moDec 2000 - Oct 2007 | — |
-61.96%Sep 1998 | 10mo 28d | 3mo 18d | 1y 2moOct 1997 - Dec 1998 | — |
Drawdown Indicators
| BIIB | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -89.98% | -56.78% | -33.20% |
Max Drawdown (1Y)Largest decline over 1 year | -14.34% | -9.10% | -5.24% |
Max Drawdown (3Y)Largest decline over 3 years | -58.64% | -18.90% | -39.74% |
Max Drawdown (5Y)Largest decline over 5 years | -67.59% | -25.43% | -42.16% |
Max Drawdown (10Y)Largest decline over 10 years | -72.66% | -33.92% | -38.74% |
Current DrawdownCurrent decline from peak | -57.36% | -1.58% | -55.78% |
Average DrawdownAverage peak-to-trough decline | -36.69% | -10.70% | -25.99% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 5.88% | 2.14% | +3.74% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Biogen Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Biogen Inc. is priced in the market compared to other companies in the Drug Manufacturers - General industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PE Ratio
The chart displays the Price-to-Earnings (P/E) ratio for BIIB, comparing it with other companies in the Drug Manufacturers - General industry. Currently, BIIB has a P/E ratio of 35.9. This P/E ratio is significantly higher than those of industry peers. This could indicate that the stock is overvalued or that investors expect strong future growth.
PEG Ratio
The chart shows the Price/Earnings to Growth (PEG) ratio for BIIB compared to other companies in the Drug Manufacturers - General industry. BIIB currently has a PEG ratio of 2.5. This PEG ratio is higher than the industry average, which may suggest the stock is overvalued relative to its expected earnings growth.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for BIIB relative to other companies in the Drug Manufacturers - General industry. Currently, BIIB has a P/S ratio of 3.0. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for BIIB in comparison with other companies in the Drug Manufacturers - General industry. Currently, BIIB has a P/B value of 1.6. This P/B ratio is low compared to industry peers. It might indicate the stock is undervalued or that the company’s assets are not expected to generate strong returns.
Income Statement
| TTM | |
|---|---|
Revenue | |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with BIIB
Add Biogen Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with BIIB